| PDE11A - Phosphodiesterase 11A | |
|---|---|
| Symbol | PDE11A |
| Full Name | Phosphodiesterase 11A |
| Chromosome | 2q31.1 |
| NCBI Gene ID | [5173](https://www.ncbi.nlm.nih.gov/gene/5173) |
| OMIM | [607429](https://www.omim.org/entry/607429) |
| Ensembl | [ENSG00000128605](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128605) |
| UniProt | [Q9UQ97](https://www.uniprot.org/uniprotkb/Q9UQ97/entry) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Depression, Cancer |
PDE11A (Phosphodiesterase 11A) is a dual-specificity cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP [1]. It belongs to the phosphodiesterase superfamily, which regulates the intracellular concentrations of second messengers critical for cellular signaling. While initially thought to have limited brain expression, recent studies have revealed important roles for PDE11A in neuronal function, synaptic plasticity, and behavior [2].
PDE11A is unique among phosphodiesterases due to its tissue-specific expression patterns and alternative splicing, which generates multiple isoforms with distinct subcellular localizations and regulatory properties [3]. The enzyme has emerged as a potential therapeutic target for neurodegenerative diseases, neuropsychiatric disorders, and endocrine conditions.
The PDE11A gene spans approximately 42 kb on chromosome 2q31.1 and encodes multiple splice variants. Four distinct isoforms have been identified in humans:
The structural differences in these isoforms confer distinct regulatory properties, including differential responses to cGMP binding and phosphorylation [4]. PDE11A contains two conserved catalytic domains connected by a regulatory region that includes a GAF domain, which binds cGMP and modulates enzyme activity.
PDE11A functions as a dual-specificity phosphodiesterase capable of hydrolyzing both cAMP and cGMP, though with different efficiencies. The enzyme has a higher affinity for cGMP (Km ~100 nM) compared to cAMP (Km ~1 μM) [5]. This dual specificity allows PDE11A to integrate signals from multiple second messenger pathways and modulate the cross-talk between cAMP and cGMP signaling.
Key regulatory mechanisms include:
PDE11A regulates several critical signaling pathways in neurons:
cAMP/PKA pathway: By hydrolyzing cAMP, PDE11A modulates PKA activity and downstream effects on transcription factors including CREB, which is crucial for memory formation [6]
cGMP/PKG pathway: PDE11A influences cGMP-dependent protein kinase signaling involved in synaptic plasticity and vascular function
Cross-talk regulation: The dual specificity of PDE11A allows it to modulate interactions between cAMP and cGMP pathways
| Partner | Interaction | Function |
|---|---|---|
| SPATA8 | Testis-specific | Male fertility |
| AKAPs | Scaffolding | Subcellular targeting |
| GAF domain proteins | Allosteric regulation | Activity modulation |
| PKA/PKG | Phosphorylation | Activity regulation |
PDE11A exhibits a distinctive expression pattern with highest levels in peripheral tissues:
In the brain, PDE11A expression is particularly notable in:
The neuronal expression of PDE11A is enriched in dendritic compartments and postsynaptic densities, consistent with its role in modulating synaptic plasticity [7].
PDE11A has emerged as a significant player in Alzheimer's disease pathogenesis [8]:
Therapeutic strategies targeting PDE11A include selective inhibitors designed to enhance cAMP/cGMP signaling and improve cognitive function.
In Parkinson's disease, PDE11A is implicated in [10]:
PDE11A has been linked to several psychiatric conditions:
PDE11A represents a promising drug target due to its tissue-specific expression and role in multiple disease contexts:
| Approach | Compound | Status |
|---|---|---|
| Selective PDE11A inhibitors | Preclinical compounds | Preclinical |
| Non-selective PDE inhibitors | Sildenafil, tadalafil | Clinical use |
| Gene therapy | AAV-mediated expression | Investigational |
The development of selective PDE11A inhibitors has been challenging due to structural similarities with other phosphodiesterases [12]. However, several compounds have shown promise in preclinical models of cognitive dysfunction and depression.
Key questions remaining about PDE11A include: